AstraZeneca (AZN) Ultomiris Gets CHMP Nod for New Rare Disease

AstraZeneca AZN announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has given a positive opinion recommending approval of its long-acting C5 complement inhibitor, Ultomiris, for a new rare disease indication in t https://www.nasdaq.com/articles/astrazeneca-azn-ultomiris-gets-chmp-nod-for-new-rare-disease